H2020 SME Grant „denovoSkin“

Project ID: 830454
Full Title: Personalized, bio-engineered skin grafts for the permanent treatment of skin defects.
EU Officer: Mr. Chrysafis Argyros

From 2018-10-01 to 2020-09-30
Funding scheme: H2020-EIC-SMEINST-2018-2020

Horizon 2020 (H2020) is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness.

CUTISS AG has been awarded an SME Instrument Phase 2 grant of €2.5 million under grant agreement No. 830454

Within the denovoSkin™ project, CUTISS will set up and validate the SkinFactory 2.0 – an automated production process to improve the scalability of denovoSkin™. SkinFactory 2.0 will be put to commercial use once Market Authorisation is granted. In the meantime, it will be used to produce skin for patients involved in the clinical trials.

The SME Instrument is a programme under the Horizon 2020 framework run by the EASME, the European Executive Agency for Small and Medium-sized Enterprises. CUTISS already secured a Phase 1 SME Instrument grant in 2018. The Phase 2 project continues the work started in Phase 1, contributing the financial resources needed to advance the market readiness.

The denovoSkin™ project will be executed from 2018 to 2022 with activities broken down into 4 Work Packages:

  1. WP1 Automation of Production Process. The automation of the process will be done by a specialised automation company to be selected by the end of 2018, supported by us.
  2. WP2 Integrated system validation
  3. WP3 Exploitation and communication of project results
  4. WP4 Project management.

Our EU Officer is Mr. Chrysafis Argyros
Linkedin Profil

The project is running in collaboration with the following partners:
Zühlke – empowering ideas
HTSS – Europe’s premier medtech market access
Renesol – Kathi Mujynya
Luzzatto & Luzzatto patent Attorneys